Ozarelix  (Synonyms: D-63153)

Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer^[1].

Ozarelix (0-20 ng/mL, 72 h) inhibits PC3 and DU145 cell proliferation^[1].
Ozarelix (0-20 ng/mL, 72 h) induces apoptosis in PC3 and DU145 cells^[1].
Ozarelix (20 ng/mL, 72 h) triggers caspase 8-dependent caspase 3 activation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1459.09

C₇₂H₉₆ClN₁₇O₁₄

295350-45-7

OC(C=C1)=CC=C1C[C@H](N(C)C([C@H](CO)NC([C@H](NC([C@H](NC([C@H](NC(C)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)CC4=CC=C(C=C4)Cl)=O)CC5=CN=CC=C5)=O)=O)C(N[C@H](CCCCNC(N)=O)C(N[C@@H](CCCC)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Festuccia C, et al. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.  [Content Brief]